Compare DERM & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DERM | UNCY |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.3M | 145.3M |
| IPO Year | 2021 | 2021 |
| Metric | DERM | UNCY |
|---|---|---|
| Price | $6.00 | $6.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $12.67 | ★ $25.67 |
| AVG Volume (30 Days) | 266.2K | ★ 699.6K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.72 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $61,858,000.00 | $675,000.00 |
| Revenue This Year | $39.72 | N/A |
| Revenue Next Year | $63.24 | $582.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.20 | N/A |
| 52 Week Low | $4.31 | $0.47 |
| 52 Week High | $9.56 | $8.74 |
| Indicator | DERM | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 38.94 |
| Support Level | $5.77 | $6.17 |
| Resistance Level | $6.59 | $7.22 |
| Average True Range (ATR) | 0.31 | 0.54 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 33.33 | 1.16 |
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.